(difelikefalin)
Some helpful resources and information on KAPRUVIA®
(difelikefalin) to
support your treatment goals for patients on in-centre HD with moderate
to severe chronic kidney disease-associated pruritus (CKD-aP)
KAPRUVIA® OVERVIEW
Download key information about CKD-aP and KAPRUVIA®, including efficacy, tolerability, mode of action and dosing
KAPRUVIA® FORMULARY PACK
Download the formulary pack to help you with your applications for implementing KAPRUVIA® as a treatment
KAPRUVIA® DOSING CARD
Find out how to dose and administer
KAPRUVIA® using this simple guide
PATIENT IDENTIFICATION
LEAVEPIECE
Learn how to identify signs of moderate-to-severe CKD-aP and diagnose patients
Kapruvia® Patient LEAFLET
Download the leaflet to help patients who have been prescribed KAPRUVIA® to learn more about the treatment
CKD-aP, chronic kidney disease-associated pruritus; HD, haemodialysis.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma UK Ltd. (Tel 01276 853633). Email: medicalinfo_UK@viforpharma.com
Welcome to
Help us guide you to the right place:
I am a UK healthcare
professional or UK healthcare
decision maker
This is me, continue 
I am not a UK healthcare
professional or UK healthcare
decision maker
This is me, continue